NOVT Corporation, formerly Novoste Corporation until it changed its name in 2006, is/was a medical device company developing a hand-held device to deliver beta, a low-penetration radiation, to the site of a treated blockage in a coronary artery. Novoste Corporation developed the Beta-Cath System, a hand-held device to deliver beta, or low penetration, radiation to the site of a treated blockage in a coronary artery to decrease the likelihood of restenosis. Restenosis, the renarrowing of a previously treated artery, is the major limitation of percutaneous coronary intervention (PTCA), a procedure used by interventional cardiologists to open blocked coronary arteries. The Beta-Cath System has been shown to reduce the incidence of restenosis in-patients who are being treated for blocked stents, or in-stent restenosis.The Beta-Cath System is designed to fitwell with techniques currently used by interventional cardiologists in the cathlab. It is a hand-held device that hydraulically delivers beta radiation sources through a closed-end catheter to the area of the coronary artery injured by the immediately preceding PTCA procedure.
